Background
Leucorrhoea is a common gynaecological condition characterized by excessive vaginal discharge, often accompanied by fatigue, pruritus, backache, and burning micturition. In Unani medicine, it is attributed to humoral imbalance and dysfunction of uterine faculties. Tiryāq-i-Raḥim, a polyherbal Unani formulation (PUF), is traditionally used for its tonic, astringent, analgesic, and phlegm-expelling properties.
Study objective
This study aimed to evaluate the safety and efficacy of PUF in women with leucorrhoea.
Methods
A prospective clinical study was conducted at Regional Research Institute of Unani Medicine, Chennai. The study was approved by the Institutional Ethics Committee on 08 September 2022 and registered with CTRI on 09 March 2023. A total of 117 female patients aged 18–40 years with symptoms of leucorrhoea were enrolled. The formulation was standardized through macroscopic, microscopic, and organoleptic evaluation of ingredients authenticated at RRIUM, Chennai. The botanical nomenclature of all plant components was verified using The Plant List (www.theplantlist.org) and compared with pharmacopoeial standards to ensure taxonomic accuracy. Quantitative phytochemical profiling (HPLC–MS) is proposed for future validation to strengthen reproducibility and quality control. PUF was administered orally (2 g twice daily) for 14 days. Symptom severity was assessed using a 10-point Visual Analogue Scale (VAS) and vaginal wet mount test. Safety was evaluated through laboratory tests. Statistical analysis was done using paired t-test and Wilcoxon signed-rank test, with p < 0.05 considered significant.
Results
After treatment, a significant reduction (p < 0.001) noted in VAS scores for all symptoms. Vaginal discharge reduced from 2.97 ± 0.15–0.52 ± 0.59, and general weakness from 5.81 ± 2.21–1.74 ± 1.28. No adverse events or laboratory abnormalities were noted. Complete relief was reported in 47.86 % of patients, with marked improvement in another 47.86 %.
Conclusion
This PUF is a safe and effective Unani formulation for managing leucorrhoea, warranting further trials for broader validation.
扫码关注我们
求助内容:
应助结果提醒方式:
